华西医学

华西医学

高原地区高血压患者降压治疗调查分析

查看全文

目的 调查高原地区高血压患者治疗率、控制率及降压治疗方案。 方法 回顾性分析西藏自治区人民政府驻成都办事处医院 2013 年 10 月—12 月住院藏族高血压患者的病历资料。 结果 共纳入患者 165 例,接受降压治疗 143 例(86.7%),降压治疗后达标 34 例(23.8%),接受降压治疗的患者依从率为 43.4%。降压方案中,单药治疗 116 例(81.1%),其中藏药、钙通道阻滞剂、利尿剂及传统复方制剂的治疗比例分别是 24.1%、21.6%、19.0%、18.1%。 结论 高血压的治疗率高,但降压治疗的依从性和控制率低。需加强对高原地区基层医生的专业知识培训,同时加强高血压患者的健康教育。

Objective To explore the effect of antihypertensive therapy for hypertension patients from plateau area. Method A retrospective analysis of medical records for Tibetan patients with hypertension from October to December 2013 in Hospital of Chengdu Office of People’s Government of Tibetan Autonomous Region. Results The study recruited 165 patients. The rate of treatment, control, and compliance of hypertension patients were 86.7% (143/165), 23.8% (34/143), 43.4% (62/143), respectively. The main characteristics of hypertension treatment were higher proportions of single-drug therapy (81.1%, 116/143); among those the Tibetan drug (24.1%), calcium channel blockers (21.6%), diuretics (19.0%), and traditional compound preparation (18.1%) were most commonly used in the antihypertensive therapy. Conclusions The rate of treatment was high, but the rate of control and compliance were low in Tibetan patients with hypertension. It was necessary to carry out hypertension education to patients and strengthen the training of doctors at the plateau.

关键词: 高原; 高血压; 降压药物

Key words: Plateau; Hypertension; Antihypertensive

引用本文: 赵丽明, 李晓萍, 周瑶, 李洪卫, 贺斌, 刘兰昕, 杜薇, 吴勇, 马敏, 黄方洋, 付永兴, 祝烨. 高原地区高血压患者降压治疗调查分析. 华西医学, 2018, 33(3): 317-320. doi: 10.7507/1002-0179.201603183 复制

登录后 ,请手动点击刷新查看全文内容。 没有账号,
登录后 ,请手动点击刷新查看图表内容。 没有账号,
1. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics——2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation, 2009, 119(3): e21-181.
2. 中华人民共和国国家卫生和计划生育委员会. 2011中国卫生统计年鉴. (2011-01-16)[2016-03-11]. http://www.nhfpc.gov.cn/ htmlfiles/zwgkzt/ptjnj/year2011/index2011.html.
3. Sun SF. Epidemiology of hypertension on the Tibetan Plateau. Hum Biol, 1986, 58(4): 507-515.
4. Li K, Liang Y, Sun Y, et al. The relationship between polymorphisms at 17 gene sites and hypertension among the Aboriginal Tibetan People. Biomed Environ Sci, 2012, 25(5): 526-532.
5. Schapira MM, Fletcher KE, Hayes A, et al. The development and validation of the hypertension evaluation of lifestyle and management knowledge scale. J Clin Hypertens (Greenwich), 2012, 14(7): 461-466.
6. 中国高血压防治指南修订委员会. 中国高血压防治指南2010. 中国医学前沿杂志: 电子版, 2011, 3(5): 42-93.
7. Zheng X, Yao DK, Zhuo-Ma CR, et al. Prevalence, self-awareness, treatment, and control of hypertension in Lhasa, Tibet. Clin Exp Hypertens, 2012, 34(5): 328-333.
8. Yang S, Liu S, Wang Y, et al. High blood pressure in Chinese ethnic minorities: report from rural Yunnan province. Am J Hypertens. 2011, 24(11): 1209-1214.
9. Zhao X, Li S, Ba S, et al. Prevalence, awareness, treatment, and control of hypertension among herdsmen living at 4,300 m in Tibet. Am J Hypertens, 2012, 25(5): 583-589.
10. Sherpa LY, Stigum H, Chongsuvivatwong V, et al. Prevalence of metabolic syndrome and common metabolic components in high altitude farmers and herdsmen at 3700 m in Tibet. High Alt Med Biol, 2013, 14(1): 37-44.
11. Mingji C, Onakpoya IJ, Perera R, et al. Relationship between altitude and the prevalence of hypertension in Tibet: a systematic review. Heart, 2015, 101(13): 1054-1060.
12. Liu L, Liu L, Ding Y, et al. Ethnic and environmental differences in various markers of dietary intake and blood pressure among Chinese Han and three other minority peoples of China: results from the WHO Cardiovascular Diseases and Alimentary Comparison (CARDIAC) Study. Hypertens Res, 2001, 24(3): 315-322.
13. Xu S, Jiayong Z, Li B, et al. Prevalence and clustering of cardiovascular disease risk factors among Tibetan adults in China: a population-based study. PLoS One, 2015, 10(6): e0129966.
14. 黄宇, 陈彦, 王张, 等. 基于药品说明书的规范化开展藏成药标准化研究——以七十味珍珠丸为例. 成都: 2011全国藏医药学术研讨会, 2011: 414-421.